Actively Recruiting
Phase 2a Randomized Study of DARE-HPV for Persistent High-Risk Human Papillomavirus Infection Comparing Dose and Treatment Duration
Led by Daré Bioscience, Inc. · Updated on 2026-10-29
118
Participants Needed
10
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating whether DARE-HPV can treat women with persistent high-risk human papillomavirus hrHPV infections. The study focuses on genital infections caused by hrHPV types 16, 18, or others, aiming to determine if the infection clears after treatment. This Phase 2a trial compares different doses and treatment durations to understand preliminary effectiveness. Participants will be assigned to one of six groups receiving either low or high doses of DARE-HPV for 14 or 21 days, or placebo for the same durations. The study drug is a vaginal capsule containing lopinavirritonavir. Treatment is randomized and double-blinded, ensuring participants and researchers do not know the assigned group. During the study, participants will attend visits for screening and treatment monitoring, complete daily diaries, and undergo genital hrHPV testing at intervals including 30, 60, and 90 days to measure infection clearance. Safety and health status are carefully monitored throughout. The study period extends through these assessments to evaluate the drugs preliminary efficacy.
CONDITIONS
Brief Title
A Study of the Preliminary Efficacy of DARE-HPV to Treat High-risk Persistent Human Papillomavirus (hrHPV)
Research Team
J
Jessica Hatheway, MBA
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here